Source: International Congress 2017 – IPF: from the bench to the bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Kataoka (Seto, Aichi, Japan). Effect of nintedanib on multidimensional evaluation in patients with IPF. 3810

Member's Comments

No comment yet.

Related content which might interest you: Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020 Effects of Hochuekkito combined with pulmonary rehabilitation in patients with COPD Source: International Congress 2017 – Latest insights into pulmonary rehabilitation in COPD Year: 2017 Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Efficacy and safety of nintedanib in the elderly patient with IPF Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Clinical and functional effectiveness of roflumilast in severe COPD patients Source: Annual Congress 2013 –Modern approach to various clinical settings Year: 2013 Concomitant medications and efficacy of nintedanib in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Efficiency of different multidimensional indexes for the assessment of the risk of exacerbations in patients with COPD Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Effects of NAC on outcome variables in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 14s Year: 2004 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Effects of roflumilast in highly symptomatic COPD patients Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care Year: 2012 The clinico-immunological evaluation of the ribomunyl therapy in complex treatment of COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 674s Year: 2006 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Responsiveness of different multidimensional severity indices to pulmonary rehabilitation in patients with COPD Source: Annual Congress 2012 - Physiotherapy and rehabilitative interventions applied to different populations with respiratory impairment Year: 2012 Effect of pulmonary rehabilitation on EuroQoL in COPD patients Source: Annual Congress 2008 - Impact of rehabilitation programmes in COPD and non-COPD patients Year: 2008 Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease Source: Annual Congress 2010 - COPD: management Year: 2010